Israel Englander Monopar Therapeutics Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.59 - $0.94 $1,131 - $1,801	1,917 Added 1.0%	194,298 $141,000
Q1 2024 May 15, 2024	BUY	$0.31 - $1.35 $50,542 - $220,104	163,040 Added 555.67%	192,381 $130,000
Q4 2023 Feb 14, 2024	SELL	$0.29 - $0.6 $991 - $2,052	-3,420 Reduced 10.44%	29,341 $9,000
Q2 2023 Aug 14, 2023	BUY	$0.84 - $1.43 $27,519 - $46,848	32,761 New	32,761 $28,000
Q2 2020 Aug 14, 2020	SELL	$6.4 - $9.5 $73,632 - $109,297	-11,505 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$5.06 - $22.0 $58,215 - $253,110	11,505 New	11,505 $85,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $312M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.